Short Summary
1 Hamburg – Local Division UPC_CFI_88/2024 Preliminary Order of the Court of First Instance of the Unified Patent Court Issued: 09/09/2024 PARTIES: Roche Diabetes Care GmbH, represented by Herrn Götzl, Sandhofer Straße 116, 68305 Mannheim, Germany, Plaintiff and Counterdefendant 1
Detailed Summary
1
Hamburg – Local Division
UPC_CFI_88/2024
Preliminary Order
of the Court of First Instance of the Unified Patent Court
Issued: 09/09/2024
PARTIES:
Roche Diabetes Care GmbH, represented by Herrn Götzl, Sandhofer Straße 116, 68305 Mannheim,
Germany,
Plaintiff and Counterdefendant 1)
represented by:
Kather Augenstein Rechtsanwälte PartGmbB, Dr. Christof
Augenstein, Sophie Prudent, LL.M., Dr. Katharina Brandt,
Rechtsanwalt Knaps, Bahnstraße 16, 40212 Düsseldorf
augenstein@katheraugenstein.com
prudent@katheraugenstein.com
brandt@katheraugenstein.com knaps@katheraugenstein.com
F. Hoffmann-La Roche AG, Grenzacherstraße 124, 4058 Basel, Switzerland,
Counterdefendant 2)
represented by:
Kather Augenstein Rechtsanwälte PartGmbB, Dr. Christof
Augenstein, Sophie Prudent, LL.M., Dr. Katharina Brandt,
Rechtsanwalt Knaps, Bahnstraße 16, 40212 Düsseldorf
augenstein@katheraugenstein.com
prudent@katheraugenstein.com
brandt@katheraugenstein.com knaps@katheraugenstein.com
and
1.
Tandem Diabetes Care, Inc., represented by its legal representative, 12400 High Bluff
Drive, CA 92130, San Diego, United States of America,
Defendant 1)
2
2.
Tandem Diabetes Care Europe B.V., .represented by its legal representative, Schiphol Boulevard
359, WTC Schiphol Airport, D-Tower 11th floor, 1118 BJ, Schiphol, Netherland,
Defendant 2)
3.
VitalAire GmbH, represented by its legal representative, von Bornbarch 2, 22848 Norderstedt,
Deutschland
Defendant 3) and Counterclaimant
Defendant 1) und 2) represented by: Taylor Wessing N.V., Charlotte Garnitsch (111867/2023), Dr. Wim
Maas (112021/2023), Iris van der Heijdt, Pauline Springorum,
Kennedyplein 201, 5611 ZT Eindhoven, NL,
c.garnitsch@taylorwessing.com
w.maas@taylorwessing.com
Defendant 3) represented by:
Hoyng Rokh Monegier, Dr. Christine Kanz, Steinstraße 20,
40212 Düsseldorf,
christine.kanz@hoyngrokh.com
Patent at issue
Patent no.
Proprietor
EP2196231
Roche Diabetes Care GmbH, F.Hoffmann-La Roche AG
Deciding Judges:
This order is issued by
Presiding Judge and Judge Rapporteur Sabine Klepsch
Legally qualified judge Dr. Stefan Schilling
Legally qualified Judge Dr. Tatyana Zhilova
Technically qualified Judge Giorgio Checcacci
Language of Proceedings:
English
Subject-Matter of the Proceedings:
Patent infringement
Request to stay proceedings
Statement of the forms of order sought by the parties:
The requesting parties, defendants 1) and 2), with the consent of the defendant 3), are
requesting:
3
I.
to stay the infringement action with Ref. 10800/2024 (the ‘Infringement Action’)
pursuant to Rules 295(f) and (m), 75 and 37(4) of the Rules of Procedure and Articles
33(5) and 33(3)(b) UPCA
II.
in the meantime, based on Rule 295(m) in conjunction with Rule 9 of the Rules of
Procedure to stay the infringement proceedings until the court has ruled on Request I.
The respondent, claimant, is requesting:
1.
Dismissal of the defendants‘ application for stay of the present proceedings,
2.
to decide, pursuant to Rule 37.2 of the Rules of Procedure, to hear the proceedings
under Art. 33(3) UPCA together before the Local Division Hamburg.
of Facts:
The Claimant alleges infringement of European Patent 2 196 231 by the defendants‘ t:slim X2
insulin pump with the interchangeable t:slim X2 reservoir (attacked embodiment). Defendant 1) is
a US manufacturer of medical devices based in San Diego, California. The company develops
medical technologies for the treatment of diabetes and in particular for insulin infusion therapy.
Its products include insulin pumps, such as the t:slim X2 insulin pump. Defendant 2) is the
importer and operates the Dutch distribution centre of Defendant 1) for Europe. Defendant 3) is a
German healthcare company with its headquarters in Norderstedt. It offers holistic solutions and
concepts for home therapy. In particular, it distributes insulin therapy produ
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Hamburg (DE) Local Division. Understanding the court's reasoning in Tandem Diabetes Care, Inc., Tandem Diabetes Care Europe B.V., vs Respondent is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Rematec GmbH & Co KGvsEurope Forestry B.V.
The Court of Appeal of the Unified Patent Court refused leave to appeal against an order of the Local Division Mannheim that had rejected Rematec's two cost determination applications as time-barred and dismissed its applications for reinstatement. The Court held that an application for leave to appeal under Rule 157 in conjunction with Rule 221 of the Rules of Procedure is inadmissible insofar as it is directed against the rejection of a reinstatement application, since Rule 320.7 expressly precludes appeals against orders on reinstatement. The Court also rejected Europe Forestry's request to impose costs on Rematec, noting that cost reimbursement is generally not available in cost determination proceedings.
Rematec GmbH & Co KGvsEurope Forestry B.V.
The Court of Appeal of the Unified Patent Court refused leave to appeal against an order of the Local Division Mannheim that had rejected Rematec's two cost determination applications as time-barred and denied reinstatement into the missed deadlines. The Court of Appeal held that an application for leave to appeal under R. 157 and R. 221 RoP is inadmissible insofar as it challenges the rejection of a reinstatement application, because R. 320.7 RoP expressly excludes appeals against orders on reinstatement. No arguable grounds for leave to appeal were identified regarding the rejection of retroactive deadline extension requests.
Promosome LLC and The Scripps Research InstitutevsBioNTech SE, BioNTech Manufacturing GmbH, BioNTech Manufacturing Marburg GmbH, BioNTech Innovative Manufacturing Services GmbH, BioNTech Europe GmbH, Pfizer Manufacturing Belgium NV, Pfizer SAS, Pfizer AB, and Pfizer, Inc.
This order of the Court of Appeal of the Unified Patent Court concerns three appeals (UPC-CoA-146/2026, UPC-CoA-147/2026, and UPC-CoA-148/2026) relating to EP 2 401 365. The appellants, Promosome LLC and The Scripps Research Institute, sought a one-month extension of the deadline for lodging their Statements of grounds of appeal, citing heavy professional workload and school holiday periods. Both groups of respondents (BioNTech and Pfizer entities) opposed the extension. The Court of Appeal rejected the applications, holding that the circumstances relied upon were foreseeable and did not justify an extension of the procedural time period.
Kodak Holding GmbH, Kodak GmbH, Kodak Graphic Communications GmbHvsFujifilm Corporation
This is a procedural order from the Court of Appeal of the Unified Patent Court concerning European Patent EP 3 511 174. The Respondents (Kodak entities) requested a one-week extension of the deadline to file written comments on the Applicant's (Fujifilm's) request for rehearing. The Court granted the extension until 23 October 2026, finding the request admissible and well-founded because the Applicant had consented, the extension was brief, and the Respondents' representatives had been occupied preparing for a related oral hearing before the Düsseldorf Regional Court that was postponed shortly before the application was filed.
Huawei Technologies Co. Ltd.vsSercomm Italia SRL
This is a procedural order from the Local Chamber Munich of the Unified Patent Court concerning alternative service of process on Sercomm Italia SRL in a patent infringement action involving European Patent EP 3 611 989 B1. After multiple failed attempts to serve the Italian defendant at its registered business address, the rapporteur had previously ordered under Rule 275.2 RoP that the prior service measures constituted valid service. The present order addresses the fact that notification of that earlier order was unsuccessful and directs additional means of notification to ensure the defendant is informed.
Network System Technologies LLCvsQualcomm Incorporated, Qualcomm Technologies, Inc., Qualcomm Germany GmbH
The Court of Appeal of the Unified Patent Court rejected Network System Technologies LLC's (NST) applications for re-establishment of rights under R. 320 RoP. NST had sought to revive its late-filed appeals against the rejection of its R. 190 Applications (production of evidence) in three infringement proceedings against Qualcomm before the Munich Local Division. The Court held that NST failed to demonstrate that all due care had been taken, as the circumstances cited did not constitute exceptional circumstances or excusable error under the precedent set in AIM v Supponor.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.